Pazenir Overview

Pazenir is used to treat the following cancers in adults:

  • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body;

  • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.

Pazenir contains the active substance paclitaxel attached to a human protein called albumin and is a ‘generic medicine’. This means that Pazenir contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Abraxane.

Pazenir is given as an infusion into a vein over a period of 30 minutes. In metastatic breast cancer, Pazenir is given on its own every three weeks. The recommended dose is 260 mg per square metre of body surface area (calculated using the patient’s height and weight).

In non-small cell lung cancer, treatment is carried out in 3-week cycles with Pazenir given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Pazenir. The recommended dose of Pazenir is 100 mg per square metre of body surface area.

Pazenir should only be given under the supervision of a specialist cancer doctor in units that are specialised in giving ‘cytotoxic’ (cell-killing) medicines. It should not be interchanged with other medicines containing paclitaxel. The medicine can only be obtained with a prescription.

For more information about using Pazenir, see the package leaflet or contact your doctor or pharmacist.

The active substance in Pazenir, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes’. Paclitaxel blocks a stage of cell division in which the cell’s internal ‘skeleton’ is dismantled to allow the cell to divide. By keeping this structure intact, the cells cannot divide and they eventually die. Pazenir also affects non-cancer cells such as blood and nerve cells, which can cause side effects.

Paclitaxel has been available as a cancer medicine since 1993. In Pazenir, as in its reference medicine Abraxane, paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles’.

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Abraxane, and do not need to be repeated for Pazenir.

As for every medicine, the company provided studies on the quality of Pazenir. There was no need for ‘bioequivalence’ studies to investigate whether Pazenir is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Pazenir is given by infusion into a vein and the nanoparticles it contains rapidly separate into its constituent parts in the same way as Abraxane’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Pazenir has been shown to be comparable to Abraxane. Therefore, the Agency’s view was that, as for Abraxane, the benefit of Pazenir outweighs the identified risk and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pazenir have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pazenir are continuously monitored. Side effects reported with Pazenir are carefully evaluated and any necessary action taken to protect patients.

Pazenir received a marketing authorisation valid throughout the EU on 6 May 2019.

What are the risks associated with Pazenir?

Because Pazenir is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Owner of copyright and other intellectual property rights to European Medicines Agency

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Find more drugs

CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR)


At one place know the best information on various cancer drugs and common symptoms associated.

CANKADO’s PRO-react Onco helps efficient patient physician communication in the treatment phase.


© 2021 Cancer.Cankado. All rights Reserved

CANKADO is approved as an active Class I medical device within the European Union (registration number DE/CA59/11976/2017) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B.

Auto Translate »

CANKADO processes information about your visit on this website using cookies. These are required to ensure the correct functionality of the homepage, to improve its performance and our third-party services. These services cannot be used without your consent.